HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01685931

A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics

Researchers studied Paliperidone Palmitate to find out how it affected psychotic symptoms in people with schizophrenia.

Medication studyAges 18–65China
The study in practice

Understand this study

What did researchers investigate?

Researchers studied Paliperidone Palmitate to find out how it affected psychotic symptoms in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Baoding and 16 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study clarity

Study information

Study start dateNovember 2012
Recruitment status
Completed
Enrollment listed in the registry
617
Sponsor
Xian-Janssen Pharmaceutical Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
China
Age range
From 18 Years to 65 Years
Official registry ID
NCT01685931
Official title
Show the full official title

Effectiveness, Safety and Tolerability of Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics and With Acute Symptom of Schizophrenia: A 13-Week, Open-label, Single-arm, Multicenter, Prospective, Interventional Study Followed by a Naturalistic Additional 1 Year Follow up

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Baoding · Beijing · Chengdu

14 more locations
  • Chongqing
  • Fuzhou
  • Guangzhou
  • Hangzhou
  • Jinan
  • Nanjing
  • Qingdao
  • Shantou
  • Shenzhen
  • Shijiazhuang
  • Suzhou
  • Taiyuan
  • Tianjin
  • Wuhan
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

Researchers studied Paliperidone Palmitate to find out how it affected psychotic symptoms in people with schizophrenia.

Who is behind this study?

The study sponsor is Xian-Janssen Pharmaceutical Ltd., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone Palmitate.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies